Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)

Prior treatment

• Immunocompromised patients, or patients who are still receiving systemic steroids (prednisone \> 10 mg/day or equivalent) or other forms of immunosuppressive therapy within 7 days before the first dose of neoadjuvant therapy in this study;
• Patients with active infections requiring systemic treatment within 7 days before the first neoadjuvant therapy in this study;
• Patients who are currently participating in any other clinical study.
  • Cohort B - Surgery-contraindicated ESCC:

Other illness

• Patients with potential tracheoesophageal fistula or aortoesophageal fistula;
• Patients with other malignancies that have not been cured within the past 2 years (except for cured basal cell carcinoma of the skin and cured carcinoma in situ of the cervix);
• Patients with active autoimmune diseases or a history of autoimmune diseases or symptoms that require systemic corticosteroid treatment or anti-autoimmune drug therapy;
• Patients with a history of allogeneic organ or stem cell transplantation;
• Patients with allergies to drugs or related components involved in this study;
• Patients with allergies to the drugs or related components involved in this study;

Other

• Patients with severe malnutrition or requiring tube feeding;
• Patients who are currently participating in any other clinical study.

• Age range: 18-80 years old;
• Patients diagnosed with esophageal squamous cell carcinoma (ESCC) through histopathological examination of biopsy tissues from the primary tumor;
• Patients with potentially resectable esophageal cancer confirmed by imaging and endoscopic examinations (T1b-3, N0, M0, with a tumor size not exceeding 5 cm and occupying less than 2/3 of the luminal circumference); Patients who have not received any antitumor treatment, including but not limited to surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy;
• Patients with a preoperative Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• Patients with a preoperative American Society of Anesthesiologists (ASA) physical status classification of I-III;
• Female patients of reproductive age should have a negative pregnancy test and be willing to use effective contraceptive methods during the study period;
• Patients who have signed the informed consent form.
• Individuals aged above 18 years;
• Patients diagnosed with esophageal squamous cell carcinoma through histopathological examination of biopsy tissues from the primary tumor;
• Patients with esophageal cancer deemed as surgically contraindicated (including those with cervical esophageal cancer, surgical contraindications, those who refuse surgery, or those considered high-risk for esophagectomy, defined as having at least one of the following characteristics: (1) age over 75 years, (2) Charlson comorbidity index \>= 2, (3) presence of moderate lung dysfunction, (4) malnutrition (with a body mass index below 18 kg/m\^2)), with a clinical staging of cT1b-3N0M0, a tumor size not exceeding 5 cm, and occupying less than 2/3 of the luminal circumference;
• Patients who have not undergone any antitumor treatment, including but not limited to surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy;
• Female patients of reproductive age should have a negative pregnancy test and be willing to adopt effective contraceptive measures during the study period;
• Patients who have signed the informed consent form.

Criteria the registry did not label

• Cohort A - Potentially resectable ESCC: